Investor Presentaiton

Hong Kong IPOs: 2020 highlights While the global IPO momentum has been affected due to the ongoing COVID-19 outbreak, the Hong Kong IPO market has shown strong resilience and vitality, ranking second globally in terms of total proceeds in 2020 YTD. During the period, 140 IPOs are expected to be completed, raising a total of HKD 389.9 billion. This represents a 24 percent increase in terms of funds raised compared with the same period last year and is in fact the most active year since 2011. The increase in fundraising is mainly attributable to homecoming listings, which benefits the city's financial industry and the capital market. During the period, nine US-listed, Chinese-based companies have completed secondary listings, raising a total of HKD 131.3 billion, representing approximately 34 percent of funds raised. These secondary listings signify Hong Kong's solid fundamentals and its importance as an international capital-raising venue with a growing ecosystem for innovation and new- economy companies. The ecosystem has further cultivated the development and fundraising for healthcare and life sciences companies, and Hong Kong has already become the largest in Asia and the second-largest biotech IPO market in the world. During the year, 22 healthcare/life sciences companies have been listed, raising a total of HKD 98.8 billion, contributing 25 percent of total funds raised. Out of these companies, 14 pre- revenue biotech companies were listed under Chapter 18A, raising an aggregate of HKD 41.1 billion. Note: (1) All analysis is based on a combination of data as at 6 December 2020 and KPMG estimates, unless otherwise stated. Excludes listings by introduction. KPMG © 2020 KPMG, a Hong Kong partnership and a member firm of the KPMG global organisation of independent member firms affiliated with KPMG International Limited ("KPMG International"), a private English company limited by guarantee. All rights reserved. 18

View entire presentation